3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Buy
86
SLNO Quote, Financials, Valuation and Earnings
Last price:
$70.67
Seasonality move
:
2.33%
Day range:
$69.87 - $73.94
52-week range:
$36.61 - $73.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,667.46x
P/B ratio:
13.37x
Volume:
4M
Avg. volume:
1.5M
1-year change:
66.94%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$4.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -- | -- | -- | $102.13 |
|
AARD
Aardvark Therapeutics
|
-- | -$0.71 | -- | -- | $32.33 |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
KRYS
Krystal Biotech
|
$99.2M | $1.39 | 121.14% | 497.44% | $214.80 |
|
LEGN
Legend Biotech
|
$192.6M | -$0.29 | 104.21% | -8.33% | $78.01 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
$71.45 | $102.13 | $3.3B | -- | $0.00 | 0% | 3,667.46x |
|
AARD
Aardvark Therapeutics
|
$7.51 | $32.33 | $160.5M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI
|
$0.23 | $8.00 | $17.8M | -- | $0.00 | 0% | -- |
|
KRYS
Krystal Biotech
|
$180.30 | $214.80 | $5.2B | 60.30x | $0.00 | 0% | 18.43x |
|
LEGN
Legend Biotech
|
$33.93 | $78.01 | $6.2B | -- | $0.00 | 0% | 9.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -2.069 | -- | -- |
|
AARD
Aardvark Therapeutics
|
-- | 0.000 | -- | -- |
|
CVM
CEL-SCI
|
-- | 1.752 | -- | -- |
|
KRYS
Krystal Biotech
|
-- | 1.671 | -- | 6.89x |
|
LEGN
Legend Biotech
|
22.45% | 1.522 | 5.04% | 4.49x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics
|
-- | -$58.8M | -- | -- | -- | -$24M |
|
AARD
Aardvark Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -$6.9M | -- | -- | -- | -$4.2M |
|
KRYS
Krystal Biotech
|
$86.2M | $41.4M | 10.49% | 10.49% | 45.4% | $52M |
|
LEGN
Legend Biotech
|
$112.6M | -$74.4M | -12.31% | -15.44% | 24.48% | -$84.5M |
Soleno Therapeutics vs. Competitors
-
Which has Higher Returns SLNO or AARD?
Aardvark Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat Aardvark Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- AARDAardvark Therapeutics-- -- -- -
What do Analysts Say About SLNO or AARD?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 42.93%. On the other hand Aardvark Therapeutics has an analysts' consensus of $32.33 which suggests that it could grow by 330.82%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 AARDAardvark Therapeutics2 0 0 -
Is SLNO or AARD More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Aardvark Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or AARD?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aardvark Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Aardvark Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or AARD?
Soleno Therapeutics quarterly revenues are --, which are smaller than Aardvark Therapeutics quarterly revenues of --. Soleno Therapeutics's net income of -$56M is higher than Aardvark Therapeutics's net income of --. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Aardvark Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,667.46x versus -- for Aardvark Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,667.46x -- -- -$56M AARDAardvark Therapeutics-- -- -- --
-
Which has Higher Returns SLNO or CVM?
CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- CVMCEL-SCI-- -$0.11 -- -
What do Analysts Say About SLNO or CVM?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 42.93%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3372.22%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 CVMCEL-SCI1 0 0 -
Is SLNO or CVM More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.
-
Which is a Better Dividend Stock SLNO or CVM?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or CVM?
Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$56M is lower than CEL-SCI's net income of -$7.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,667.46x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,667.46x -- -- -$56M CVMCEL-SCI-- -- -- -$7.1M
-
Which has Higher Returns SLNO or KRYS?
Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 49.9%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 10.49%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- KRYSKrystal Biotech94.57% $1.52 $946.4M -
What do Analysts Say About SLNO or KRYS?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 42.93%. On the other hand Krystal Biotech has an analysts' consensus of $214.80 which suggests that it could grow by 19.14%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 KRYSKrystal Biotech8 1 0 -
Is SLNO or KRYS More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.751, suggesting its less volatile than the S&P 500 by 24.867%.
-
Which is a Better Dividend Stock SLNO or KRYS?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or KRYS?
Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $91.1M. Soleno Therapeutics's net income of -$56M is lower than Krystal Biotech's net income of $45.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 60.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,667.46x versus 18.43x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,667.46x -- -- -$56M KRYSKrystal Biotech18.43x 60.30x $91.1M $45.5M
-
Which has Higher Returns SLNO or LEGN?
Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics-- -$1.27 -- LEGNLegend Biotech60.37% $0.14 $1.3B -
What do Analysts Say About SLNO or LEGN?
Soleno Therapeutics has a consensus price target of $102.13, signalling upside risk potential of 42.93%. On the other hand Legend Biotech has an analysts' consensus of $78.01 which suggests that it could grow by 129.92%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics5 0 0 LEGNLegend Biotech11 2 0 -
Is SLNO or LEGN More Risky?
Soleno Therapeutics has a beta of -2.285, which suggesting that the stock is 328.466% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or LEGN?
Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or LEGN?
Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,667.46x versus 9.89x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics3,667.46x -- -- -$56M LEGNLegend Biotech9.89x -- $186.5M $26.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 19.51% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 13.35% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 3.44% over the past day.
